Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study

[1]  A. Urban,et al.  Therapeutic drug monitoring of atypical antipsychotics. , 2017, Psychiatria polska.

[2]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[3]  D. Ochoa,et al.  Polymorphisms in CYP2D6 have a Greater Effect on Variability of Risperidone Pharmacokinetics than Gender , 2015, Basic & clinical pharmacology & toxicology.

[4]  D. L. Souza,et al.  Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs , 2014, Psychiatric Quarterly.

[5]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[6]  M. Shimizu,et al.  A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[7]  Hea‐Young Cho,et al.  Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1 , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[9]  S. Caroff,et al.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. , 2011, Neurologic clinics.

[10]  G. Masi,et al.  Management of Schizophrenia in Children and Adolescents , 2011, Drugs.

[11]  A. Mrhar,et al.  A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  W. Gaebel,et al.  Side effects of atypical antipsychotics: a brief overview , 2008, World psychiatry : official journal of the World Psychiatric Association.

[13]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[14]  H. Möller,et al.  Risperidone plasma levels, clinical response and side–effects , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[15]  K. Ha,et al.  Metric characteristics of the drug‐induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug‐induced movement disorders , 2002, Movement disorders : official journal of the Movement Disorder Society.

[16]  Toshiya Inada,et al.  Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol , 2002, Schizophrenia Research.

[17]  K. Chiba,et al.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. , 2000, British journal of clinical pharmacology.

[18]  R. Ropert,et al.  [Four years of experience with chlorpromazine in therapy of psychoses]. , 1956, La Presse medicale.

[19]  H. Hayashi,et al.  Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. , 2017, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[20]  E. Spina,et al.  Clinical applications of CYP genotyping in psychiatry , 2014, Journal of Neural Transmission.

[21]  稲田 俊也.  DIEPSS : a second-generation rating scale for antipsychotic-induced extrapyramidal symptoms : drug-induced extrapyramidal symptoms scale , 2009 .

[22]  M. Hiratsuka,et al.  Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. , 2005, Drug metabolism and pharmacokinetics.